MedTrace Logo

Effect of Tramadol in Prevention of Postpartum Depression

NCT03309163 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1230

Last updated 2019-08-14

No results posted yet for this study

Summary

The incidence of postpartum depression in Europe and the United States is about 10%, while in China the incidence rate of 15.7-39.8%. Postpartum depression is one of the most common diseases of perinatal distress, but the current research of high-quality prevention and treatment of postpartum depression is still very lack. The study suggests that the risk of postpartum depression in cesarean delivery is significantly higher than that in vaginal delivery. Therefore, postpartum depression in cesarean delivery may require more attention and treatment.Tramadol is a non-opioid central analgesic that relieves common to severe pain, and tramadol has an inhibitory effect on norepinephrine and serotonin systems and has the potential to reduce depression and anxiety. Therefore, for the analgesic demand and antidepressant demand for maternal who undergoing cesarean section, tramadol may be an optimized and effective analgesic for the prevention and treatment of postpartum depression.

Conditions

  • Caesarean Section

Interventions

DRUG

Tramadol

Patient-controlled intravenous analgesia with Tramadol

DRUG

Hydromorphone

Patient-controlled intravenous analgesia with Hydromorphone

DRUG

Ropivacaine (Epidural analgesia)

Patient-controlled epidural analgesia with Ropivacaine.

Sponsors & Collaborators

  • Xinqiao Hospital of Chongqing

    lead OTHER

Principal Investigators

  • Hong Li, M.D. · Department of Anesthesiology, Xinqiao Hospital, Third Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-09
Primary Completion
2019-06-13
Completion
2019-08-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03309163 on ClinicalTrials.gov